Skip to main content
SpringerLink
Log in

Nebivolol Versus Metoprolol in the Treatment of Hypertension

  • Section 4
  • Published:
Drug Investigation Aims and scope Submit manuscript

Summary

The efficacy and safety of 2 cardioselective β-blockers, metoprolol 100mg twice daily and nebivolol 5mg once daily, were compared in 155 patients with mild to moderate hypertension in a double-blind multicentre parallel-group study, which comprised an initial placebo phase followed by 3 months of active treatment.

Complete normalisation of blood pressure was achieved in 79% of patients in the nebivolol group and 66% in the metoprolol group. There were fewer adverse reactions in the nebivolol group and only those patients receiving metoprolol (n = 3) had to discontinue treatment because of adverse effects. Nebivolol has the advantages of low dosage and once-daily administration which aid patient compliance; this is particularly important as treatment for hypertension is prolonged.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Kirkendall WM. Beta-adrenoceptors for the treatment of hypertension. In Kostis JB, DeFelice EA (Eds) Beta-blockers in the treatment of cardiovascular disease, pp. 57–73, Raven Press, New York, 1984

    Google Scholar 

  • Nadelmann J, Frishman WH. Clinical use of beta-adrenoceptor blockade in systemic hypertension. Drugs 36: 616–632, 1988

    Article  Google Scholar 

  • Nebivolol Investigators Brochure 3rd ed., May 1989

  • Van Bortel J, Joosten J, Breed H, Kragten J, Lustermans F, et al. Quality of life with nebivolol. International Symposium on cardiovascular disease and beta-adrenoceptor function. T Elzenveld, St Elizabeth Ziekenhuis, Antwerp, 1988

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Postgraduate Medical Institute, Prague, Czechoslovakia

    O. Uhlíř, K. Lefflerová & J. Widimský

  2. Department of Medicine, Regional Hospital, Ústí nad Labem, Czechoslovakia

    M. Fejfuša

  3. II. Department of Medicine, Regional Hospital, České Budějovice, Czechoslovakia

    K. Havránek

  4. II. Department of Medicine, Charles University, Prague, Czechoslovakia

    J. Vojáček

  5. Department of Cardiology, Policlinic, Prague, Czechoslovakia

    J. Winterová

  6. I. Department of Medicine, Masaryk’s University, Brno, Czechoslovakia

    K. Zeman

Authors
  1. O. Uhlíř
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Fejfuša
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Havránek
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Lefflerová
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Vojáček
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Widimský
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Winterová
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K. Zeman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Uhlíř, O., Fejfuša, M., Havránek, K. et al. Nebivolol Versus Metoprolol in the Treatment of Hypertension. Drug Invest 3 (Suppl 1), 107–110 (1991). https://doi.org/10.1007/BF03258273

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03258273

Keywords

Search

Navigation